In the US IPO market’s busiest week since 2004, 19 IPOs raised nearly $10 billion, led by Chinese ride-hailing giant DiDi Global (DIDI). The second largest IPO of the year, DiDi (DIDI) upsized and priced at the...read more
Acumen Pharmaceuticals, a Phase 1 biotech developing a monoclonal antibody for Alzheimer's disease, raised $160 million by offering 10 million shares at $16, the high end of the range of $14 to $16. The company offered 1.7 million more shares than anticipated. ...read more
17 IPOs are slated to raise $9.1 billion in the week ahead, led by long-awaited Chinese ride-hailing giant DiDi Global (DIDI).
DiDi (DIDI) plans to raise $3.9 billion at a $67.5 billion market cap. DiDi is China’s...read more
Acumen Pharmaceuticals, a Phase 1 biotech developing a monoclonal antibody for Alzheimer's disease, announced terms for its IPO on Thursday. The Charlottesville, VA-based company plans to raise $125 million by offering 8.3 million shares at a price range of $14...read more
US IPO Weekly Recap: DiDi leads a 19 IPO week, the busiest since 2004
In the US IPO market’s busiest week since 2004, 19 IPOs raised nearly $10 billion, led by Chinese ride-hailing giant DiDi Global (DIDI). The second largest IPO of the year, DiDi (DIDI) upsized and priced at the...read more
Alzheimer's biotech Acumen Pharmaceuticals prices upsized IPO at $16 high end
Acumen Pharmaceuticals, a Phase 1 biotech developing a monoclonal antibody for Alzheimer's disease, raised $160 million by offering 10 million shares at $16, the high end of the range of $14 to $16. The company offered 1.7 million more shares than anticipated. ...read more
US IPO Week Ahead: DiDi makes its billion-dollar debut in a 17 IPO week
17 IPOs are slated to raise $9.1 billion in the week ahead, led by long-awaited Chinese ride-hailing giant DiDi Global (DIDI). DiDi (DIDI) plans to raise $3.9 billion at a $67.5 billion market cap. DiDi is China’s...read more
Alzheimer's biotech Acumen Pharmaceuticals sets terms for $125 million IPO
Acumen Pharmaceuticals, a Phase 1 biotech developing a monoclonal antibody for Alzheimer's disease, announced terms for its IPO on Thursday. The Charlottesville, VA-based company plans to raise $125 million by offering 8.3 million shares at a price range of $14...read more